Showing results (501-510 of 689) with videos related to

Sort By:
Pageof 69
American Heart Journal|January 28, 2010
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarctionJames R Harkness, Marc S Sabatine, Eugene Braunwald, et al.
Journal of Thrombosis and Thrombolysis|February 11, 2012
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparinMichael P Thomas, Kenneth W Mahaffey, Karen Chiswell, et al.
Circulation|June 22, 2011
Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The GuidelinesRobin Mathews, Eric D Peterson, Shuang Li, et al.
Clinical Cardiology|February 18, 2014
Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent RegistryMarc P Bonaca, Sabina A Murphy, Debra Miller, et al.
American Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.
European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.
European Heart Journal|November 16, 2004
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trialsC Michael Gibson, Raphaelle L Dumaine, Eli V Gelfand, et al.
American Heart Journal|January 6, 2022
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.
Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.
Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.
Pageof 69